Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganirelix + cetrorelix
- Development stage
- Unknown
- Lead developer
- Organon
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
The term "ganirelix + cetrorelix" refers to a pooled comparator group of two injectable gonadotropin-releasing hormone (GnRH) antagonists used in controlled ovarian stimulation (COS) for in vitro fertilization (IVF). Both ganirelix and cetrorelix are synthetic decapeptides that competitively bind to GnRH receptors in the pituitary gland. This binding leads to the rapid suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby preventing premature LH surges and ovulation during the stimulation phase. In clinical trial contexts, such as those sponsored by Centro A.M.B.R.A., these agents serve as the standard-of-care active comparator against novel oral GnRH antagonists like linzagolix.
- Other names
- ganirelix acetatecetrorelix acetate
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on ganirelix + cetrorelix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganirelix + cetrorelix.